SEVERITY OF ABDOMINAL OBESITY AND CARBOHYDRATE METABOLISM DISORDERS IN MENOPAUSAL WOMEN AND POTENTIALS FOR THE CORRECTION OF THE REVEALED VIOLATIONS
- Авторлар: Tolstov S.N1,2, Salov I.A1,2, Rebrov A.P1
-
Мекемелер:
- FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “
- SHCI “Saratov City Clinical Hospital № 1 n.a. Yu.Ya. Gordeyev"
- Шығарылым: № 3 (2017)
- Беттер: 36-40
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289777
- ID: 289777
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
To date, the frequency of the use of menopausal hormone therapy (MHT) for the correction of climacteric syndrome and metabolic disorders is still low due to possible complications of such therapy. Not only the low dose of estrogen, but characteristics of progestogen in the composition of combined mode of MHT have a great significance. The results of evaluation of changes in abdominal obesity (AO), and carbohydrate metabolism disorders in women in early postmenopause against the background of long-term combined MHT with 1 mg E2/2 mg drospirenone (DRSP) are presented. This study demonstrates the possibility of use of combination of 1 mg E2/2 mg DRSP for long-term MHT in women in early postmenopause with metabolic disorders.
Негізгі сөздер
Толық мәтін
Авторлар туралы
S. Tolstov
FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “; SHCI “Saratov City Clinical Hospital № 1 n.a. Yu.Ya. Gordeyev"Saratov
I. Salov
FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “; SHCI “Saratov City Clinical Hospital № 1 n.a. Yu.Ya. Gordeyev"Saratov
A. Rebrov
FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “
Email: andreyrebrov@yandex.ru
MD, Prof., Head of the Department of Hospital Therapy of the Medical Faculty Saratov
Әдебиет тізімі
- Юренева С.В., Ильина Л.М. Старение репродуктивной системы женщин: от теории к клинической практике. Часть II. Роль гормо нальной терапии в решении проблем переходного периода и ранней постменопаузы. Акушерство и гинекология. 2014;4:17-24.
- de Villiers T.J., Pines A., Panay N. Gambacciani M., Archer D.F., Baber R.J. Davis S.R., Gompel A.A., Henderson V.W. Langer R., Lobo R.A., Plu-Bureau G., Sturdee D.W.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316-37.
- Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (протокол лечения). Письмо Минздрава России от 02.10.2015 №15-4/10/2-5804.
- Baber R.J., Panay N., Fenton A., IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50.
- Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003; 68:891-905.
- Archer D. Efficacy and safety of drospirenoneestradiol for hormone therapy: a double blind, randomized multicenter trial. Menopause. 2005;12(6):716-27.
- Gambacciani M., Rosano G., Cappagli B., Pepe A., Vitale C., Genazzani A.R. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric. 2011;14:18-24.
- Григорян О.Р., Андреева Е.Н. Использование препарата «Анжели» у женщин с сахарным диабетом 2 типа и артериальной гипертензией в период постменопаузы. РМЖ. 2007;3:197-201.
- Rizzo M.R., Leo S., De Franciscis P., Colacurci N., Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/ dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age. 2014;36(1):265-74.
- Villa P., Suriano R., Ricciardi L., Tagliaferri V., De Cicco S., De Franciscis P., Colacurci N., Lanzone A. Low-doseestrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil. Steril. 2011;95:158-63.
- Репина М.А., Зинина Т.А., Кузьмина-Крутецкая С.Р. Заместительная гормональная терапия препаратом «Анжелик» состояние углеводного обмена и гемостаз. Журн. акушерства и женских болезней. 2006;1:70-5.
Қосымша файлдар
